PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) to Post FY2025 Earnings of ($1.47) Per Share, HC Wainwright Forecasts

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Investment analysts at HC Wainwright issued their FY2025 EPS estimates for shares of PMV Pharmaceuticals in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst R. Burns expects that the company will earn ($1.47) per share for the year. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for PMV Pharmaceuticals' current full-year earnings is ($1.44) per share.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08.

PMVP has been the subject of a number of other research reports. Jefferies Financial Group started coverage on shares of PMV Pharmaceuticals in a research report on Friday, April 12th. They set a "buy" rating and a $5.00 target price for the company. CLSA raised shares of PMV Pharmaceuticals to a "strong-buy" rating in a report on Monday. Finally, Craig Hallum assumed coverage on PMV Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $6.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $5.75.

PMV Pharmaceuticals Trading Up 0.9 %

PMVP traded up $0.02 on Wednesday, hitting $2.16. 398,568 shares of the company's stock traded hands, compared to its average volume of 539,125. The firm has a market cap of $111.11 million, a price-to-earnings ratio of -1.61 and a beta of 1.56. PMV Pharmaceuticals has a one year low of $1.17 and a one year high of $9.72. The company's 50 day simple moving average is $1.76 and its 200-day simple moving average is $2.00.

Institutional Trading of PMV Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio grew its position in PMV Pharmaceuticals by 174.2% in the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company's stock worth $39,000 after acquiring an additional 14,457 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of PMV Pharmaceuticals by 71.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company's stock worth $73,000 after purchasing an additional 17,858 shares during the period. Acadian Asset Management LLC increased its position in shares of PMV Pharmaceuticals by 170.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company's stock valued at $3,533,000 after purchasing an additional 1,311,745 shares during the last quarter. Vanguard Group Inc. raised its holdings in PMV Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,452,111 shares of the company's stock valued at $4,169,000 after buying an additional 46,804 shares during the period. Finally, Marquette Asset Management LLC bought a new stake in PMV Pharmaceuticals in the first quarter worth $109,000. 90.20% of the stock is currently owned by institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.